Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in End Stage Renal Disease
NCT03713190Phase 2Completed
- Sponsor
- University of Pisa
- Start
- Sep 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of empagliflozin in end stage renal disease (ESRD) (2 arms), sponsored by University of Pisa. Primary endpoint: Changes in plasma Glucose level at 2 hours. Started Sep 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT03713190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03713190.